Corcept Therapeutics (NASDAQ:CORT) Price Target Raised to $150.00 at Truist Financial
Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price target boosted by Truist Financial from $76.00 to $150.00 in a research report released on Monday,Benzinga reports. Truist Financial currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also recently weighed in on CORT. Piper Sandler upped their […]
Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price target boosted by Truist Financial from $76.00 to $150.00 in a research report released on Monday,Benzinga reports. Truist Financial currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also recently weighed in on CORT. Piper Sandler upped their […]
